Calming the Storm: A review of corticosteroid use in severely ill COVID-19 patients on mechanical ventilation

Tran Dinh, Cherie Chu

Abstract

The importance of corticosteroids in the therapy of COVID-19 has been controversial. However, as the world develops a better understanding regarding the pathophysiology of COVID-19, we are realizing that suppressing the host immune response may reduce lung inflammation preventing further complications. In addition, more high-quality randomized controlled trials, meta-analysis, and review articles are being published discussing the role of corticosteroids. Majority of these studies concluded that corticosteroids are beneficial for hospitalized severely ill COVID-19 patients requiring supplemental oxygen.

To date, therapeutic guidelines for COVID-19 patients recommend dexamethasone or other alternative corticosteroids, including methylprednisolone, hydrocortisone, or prednisone, as a treatment choice for severely ill COVID-19 patients.

This review will discuss the pharmacology, mechanism of action, pharmacodynamics, pharmacokinetics, and benefits of corticosteroids in COVID-19 patients, and review current published clinical evidence on corticosteroids.

Keywords

Corticosteroids, COVID-19, ARDS

References

1. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/.

2. World Health Organization. (‎2020)‎. Corticosteroids for COVID-19: living guidance, 2 September 2020. World Health Organization. https://apps.who.int/iris/handle/10665/334125.

3. Annane D. Corticosteroids for COVID-19. Journal of Intensive Medicine 2021; 1(1):14-25. https://doi.org/10.1016/j.jointm.2021.01.002 PMCid:PMC7919540

4. Prescott HC, Rice TW. Corticosteroids in COVID-19 ARDS: Evidence and hope during the pandemic. JAMA 2020; 324(13):1292-1295. https://doi.org/10.1001/jama.2020.16747 PMid:32876693

5. Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre randomized controlled trial. Lancet Respir Med 2020; 8(3):267-276. https://doi.org/10.1016/S2213-2600(19)30417-5

6. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384(8):693-704. https://doi.org/10.1056/NEJMoa2021436 PMid:32678530 PMCid:PMC7383595

7. Williams DM. Clinical Pharmacology of Corticosteroids. Respir Care 2018; 63(6):655-670. https://doi.org/10.4187/respcare.06314 PMid:29794202

8. Barnes PJ. Molecular mechanisms of corticosteroids in allergic diseases. Allergy 2001; 5 6(10):928-936. https://doi.org/10.1034/j.1398-9995.2001.00001.x PMid:11576070

9. Khiali S, Entezari-Maleki T. Therapeutic application of corticosteroids in COVID-19: A Focus on optimum dose and duration of therapy. J Clin Pharmacol 2021; 61(9):1145-1148. https://doi.org/10.1002/jcph.1929 PMid:34157144 PMCid:PMC8426861

10. Johns M, George S, Taburyanskaya M, et al. A Review of the evidence for corticosteroids in COVID-19. J Pharm Pract. March 2021. https://doi.org/10.1177/0897190021998502 PMid:33719698

11. Ranjbar K, Moghadami M, Mirahmadizadeh A, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis 2021; 21(1):337. https://doi.org/10.1186/s12879-021-06045-3 PMid:33838657 PMCid:PMC8035859

12. Pinzón MA, Ortiz S, Holguín H, et al. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia. PLoS One 2021; 16(5):e0252057. https://doi.org/10.1371/journal.pone.0252057 PMid:34033648 PMCid:PMC8148307

13. Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA 2020; 324(13):1307-1316. https://doi.org/10.1001/jama.2020.17021 PMid:32876695 PMCid:PMC7489411

14. Fernández-Cruz A, Ruiz-Antorán B, Muñoz-Gómez A, et al. A Retrospective controlled cohort study of the impact of glucocorticoid treatment in SARS-CoV-2 infection mortality. Antimicrob Agents Chemother 2020; 64(9):e01168-20. https://doi.org/10.1128/AAC.01168-20 PMid:32571831 PMCid:PMC7449182

15. COVID STEROID 2 Trial Group, Munch MW, Myatra SN, Vijayaraghavan BKT, et al. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: The COVID STEROID 2 Randomized Trial. JAMA 2021; 326(18):1807-1817. https://doi.org/10.1001/jama.2021.18295 PMid:34673895

17. Granholm A, Munch MW, Myatra SN, et al. Dexamethasone 12 mg versus 6 mg for patients with COVID-19 and severe hypoxaemia: a pre-planned, secondary Bayesian analysis of the COVID STEROID 2 trial. Intensive Care Med 2021; 1-11. https://doi.org/10.1007/s00134-021-06573-1

18. Annane D, Pastores SM, Rochwerg B, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Crit Care Med 2017; 45(12):2078-2088. https://doi.org/10.1097/CCM.0000000000002737 PMid:28938253

19. Dunn TE, Ludwig EA, Slaughter RL, et al. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther 1991; 49(5):536-549. https://doi.org/10.1038/clpt.1991.64 PMid:1827621

20. Erstad BL, Barletta JF. Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis. Crit Care 2021; 25(1):77. https://doi.org/10.1186/s13054-021-03495-8 PMid:33622380 PMCid:PMC7901103

21. Angus DC, Derde L, Al-Beidh F, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA 2020; 324(13):1317-1329. https://doi.org/10.1001/jama.2020.17022 PMid:32876697 PMCid:PMC7489418

22. Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial. Clin Infect Dis 2021; 72(9):e373-e381. DOI: 10.1093/cid/ciaa1177 PMID: 32785710 PMCID: PMC7454320

23. Albani F, Fusina F, Granato E, et al. Corticosteroid treatment has no effect on hospital mortality in COVID-19 patients. Sci Rep 2021; 11(1):1015. https://doi.org/10.1038/s41598-020-80654-x PMid:33441909 PMCid:PMC7806743